Glenmark Pharma’s arm to launch Leucovorin Calcium for Injection USP

11 Dec 2025 Evaluate

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is all set to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial. Glenmark’s Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Leucovorin Calcium for Injection, 350 mg/vial, of Hospira, Inc. Glenmark will begin distribution in December 2025. 

According to IQVIA sales data for the 12-month period ending October 2025, the Leucovorin Calcium for Injection, 350 mg/vial market achieved annual sales of around $16.8 million. Glenmark’s Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is only approved for the indication(s) listed in Glenmark’s approved label.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1996.55 -37.65 (-1.85%)
13-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1698.10
Dr. Reddys Lab 1267.60
Cipla 1330.85
Zydus Lifesciences 904.85
Lupin 2199.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×